Project Grant R01NS137233
Award Date
9/19/24
Completion Date
7/31/29
Dollars Obligated
$1.5M
Federal Agency
National Institute of Neurological Disorders and Stroke
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
Emigration Canyon, UT 84108, USA
Similar Awards
This $2,307,075 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports an ambitious research program at The Leland Stanford Junior University. The funded research aims to define novel mechanisms underlying human neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Parkinson's disease, and...
This $460,625 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) will support research to investigate the roles of the deubiquitylation pathway in TDP-43 pathology related to amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The award, provided to the University of Massachusetts Medical School, will utilize mouse models and...
This $121,554 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to investigate the role of RNA processing misregulation by the KIF5A gene in amyotrophic lateral sclerosis (ALS). The research aims to: (1) examine the impact of ALS-related KIF5A mutations on the proteotoxic pathway, (2) explore KIF5A interactions with other ALS-associated...
This Project Grant award of $532,381.00 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program supports research to investigate the molecular mechanisms underlying the role of the KIF5A gene variant KIF5ADE27 in the pathogenesis of amyotrophic lateral sclerosis (ALS). The key objectives are to determine the gain-of-function effects of KIF5ADE27 in...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will fund research to develop a novel cellular model for investigating amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The researchers will directly convert patient-derived fibroblasts into neurons, preserving the epigenetic age of the starting cells, in order to...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $2,001,864 to Harvard University to investigate the subcellular mechanisms underlying the selective vulnerability of specific neuron subtypes in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The researchers will quantitatively study the localization of RNA, proteins, and translational regulation in the synapses and soma of vulnerable corticospinal neurons (CSN) and...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $374,349 to the University of North Carolina at Chapel Hill to develop and optimize a new animal model for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The research aims to establish a mouse model that accurately recapitulates the human disease...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will support research into the role of TDP-43 dysfunction and neuroinflammation in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The $251,250 award, active from April 1, 2025 to March 31, 2027, will enable investigations using a mouse model of mutant TDP-43 as...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $3,841,367.00 to The Regents of the University of California, San Francisco to conduct research on understanding the role of the TBK1 protein kinase in regulating selective autophagy pathways in neurons. The goal is to gain a comprehensive understanding of how disruption of TBK1 function leads to the loss of excitatory neurons, which is a key feature of frontotemporal dementia (FTD)...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $1,499,212 Project Grant (CFDA 93.853) to Aquinnah Pharmaceuticals, Inc. to develop a novel oral brain-penetrant therapeutic for amyotrophic lateral sclerosis (ALS). The project aims to manufacture, conduct IND-enabling studies, and hold a Pre-IND meeting with the FDA for a new drug candidate designed to slow and potentially reverse the progression of ALS by reducing the accumulation of insoluble, aggregated TDP-43...